1207989-36-3

Upstream product

• 1878-67-7 3-Bromophenylacetic acid 
• 1207989-32-9 (R)-4-benzyl-3-(2-(3-bromophenyl)acetyl)oxazolidin-2-one 
• 1207989-33-0 4-{3-(4-benzyl-2-oxooxazolidin-3-yl)-2-(3-bromophenyl)-3-oxopropyl}benzoic acid tert-butyl ester 
• 540-37-4 p-aminoiodobenzene 
• 209919-30-2 4-chloro-2-methylphenylboronic acid 
• 1207989-35-2 4′-chloro-2′-methylbiphenyl-4-amine 
• 1207989-34-1 4-[2-carboxy-2-(3-bromophenyl)ethyl]benzoic acid tert-butyl ester 

Downstream Products

• 1207989-38-5 4-{(4'-chloro-2'-methylbiphenyl-4-ylcarbamoyl)-2-[3-(4,4-dimethylcyclohex-1-enyl)phenyl]ethyl}benzoic acid tert-butyl ester 
• 1207989-41-0 4-{(4'-chloro-2'-methylbiphenyl-4-ylcarbamoyl)-2-[3-(4,4-dimethylcyclohex-1-enyl)phenyl]ethyl}benzoic acid 
• 1207989-11-4 sodium 2-4-{2-(4'-chloro-2'-methylbiphenyl-4-ylcarbamoyl)-2-[3-(4,4-dimethylcyclohex-1-enyl)phenyl]ethyl}benzoylaminoethane sulfonic acid 

Relevant academic research and scientific papers

GLUCAGON ANTAGONISTS

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharm

GLUCAGON ANTAGONISTS

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharm